Cytokine Signalling Forum
CME Courses
JAK Inhibitors - Highlights from ACR 2019
Developed by CESAS Medical, under the auspices of the University of Glasgow This activity is supported by unrestricted educational grants from Pfizer Italia S.R.L. and Lilly
Estimated time to complete activity: 1 and 1/2 hours
Compatible with all modern internet browsers and mobile devices
EDUCATIONAL OBJECTIVES
After completing this activity, the learner will:
- Be familiar with the novel data on newly approved upadacitinib
- Be up to date on the new updates available on baricitinib and tofacitinib in relation to clinical practice
- Have learned the new updates on emerging JAKinibs, filgotinib
- Understand the data presented at ACR on switching and cycling
TARGET AUDIENCE
This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory disease.
PROGRAMME OVERVIEW
ACR 2019 presented new scientific and clinical information on cytokine signalling science that will shape the rheumatology treatment landscape. Data presented included those relating to recently approved cytokine signalling agents, JAK inhibitors in clinical practice and those currently in development.
In this activity, JAK Inhibitors – Highlights from ACR 2019, international experts discuss key abstracts and data from ACR 2019 specifically relating to cytokine signalling. The 4 distinct modules in this course focus on a newly approved JAK inhibitor, established JAK inhibitors in clinical practice, emerging JAK inhibitors in phase 3, and data from ACR on treatment strategies such as switching and cycling.
This course, JAK Inhibitors – Highlights from ACR 2019, outlines recent developments in cytokine signalling science in rheumatoid arthritis, and discusses the importance of these new data for clinical practice. The learner’s understanding of the information presented will be assessed following each of the course modules.
INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.
DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.
ACCREDITATION STATEMENT
The e-learning activity, JAK Inhibitors - Highlights from ACR 2019, organised by CESAS Medical, under the auspices of the University of Glasgow, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The e-learning activity, JAK Inhibitors - Highlights from ACR 2019, organised by CESAS Medical, under the auspices of the University of Glasgow, is awarded 1 European CME credits (ECMECs).
Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
| Module | Presenter | Video | Questions |
|---|---|---|---|
| Introduction |
Professor Leonard Calabrese
Director & Professor of Medicine, Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute. He is a graduate of the Kansas City University of Medicine and Biosciences. Completed his internal medicine training at the Cleveland Clinic Foundation in Ohio, followed by a fellowship in rheumatic and immunologic disease. Professor Calabrese has received numerous awards, including honorary Doctorates of Humane Letters from the Kansas City University of Medicine and Biosciences and Alma College and the Leonard Tow Humanitarianism in Medicine award from the Arnold P Goldman MD Foundation. He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles. |
01:46 | |
| Data on Newly Approved JAKinibs: Upadacitinib |
Professor Leonard Calabrese
Director & Professor of Medicine, Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute. He is a graduate of the Kansas City University of Medicine and Biosciences. Completed his internal medicine training at the Cleveland Clinic Foundation in Ohio, followed by a fellowship in rheumatic and immunologic disease. Professor Calabrese has received numerous awards, including honorary Doctorates of Humane Letters from the Kansas City University of Medicine and Biosciences and Alma College and the Leonard Tow Humanitarianism in Medicine award from the Arnold P Goldman MD Foundation. He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles. |
18:26 | 7 |
| Updates on Established JAKinibs |
Dr Neil Basu
Senior Clinical Lecturer of Rheumatology, Dr Basu is a Senior Clinical Lecturer at the University of Glasgow, an Honorary Consultant Rheumatologist, NHS Glasgow and is currently the elected co-chair of the UK and Ireland Vasculitis Society. He earned his Bachelor of Medicine and Bachelor of Surgery at the University of Edinburgh, went on to achieve his Postgraduate Medical Training & Training Board in the field of Rheumatology and Internal Medicine. He later went onto complete his PhD in Epidemiology. Dr Basu is a member of the UK Scleroderma study group, an associate editor for Arthritis & Rheumatology, BMC Rheumatology and F1000 Prime Faculty. He has also contributed as an author to several research papers focusing on vasculitis and inflammatory rheumatic diseases. Clinically, he has developed and now lead an almost unique multi-disciplinary vasculitis service, one of the largest in Europe and one of only two health care providers in the UK affiliated with the recently formed European Union Reference Network in vasculitis. Dr Basu’s research seeks to apply descriptively, analytical and translational epidemiological methods to better quantify the burden and determinants of systematic vasculitis with view to informing and executing clinical trials. |
22:40 | 6 |
| Newly Emerging JAKinib: Filgotinib |
Professor Kenneth Kalunian
Co-Director and Professor of Clinical Medicine, Professor Kalunian is the Co-Director of the UC San Diego Centre for Innovative Therapy, the Director of UC San Diego Lupus Centre of Excellence and is a Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego. He obtained his Medical Degree at the St. Louis University School of Medicine and completed his internal medicine residency and rheumatology fellowship at the David Geffen School of Medicine at UC Los Angeles, Professor Kalunian is a Fellow, American College of Rheumatology. His research interests focuses on innovative strategies for the treatment of patients with systemic lupus erythematosus, osteoarthritis and rheumatoid arthritis and is interested in prognostic and predictive factors for outcomes in rheumatic diseases. |
20:01 | 7 |
| Evolving RA Treatment Patterns |
Professor Leonard Calabrese
Director & Professor of Medicine, Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute. He is a graduate of the Kansas City University of Medicine and Biosciences. Completed his internal medicine training at the Cleveland Clinic Foundation in Ohio, followed by a fellowship in rheumatic and immunologic disease. Professor Calabrese has received numerous awards, including honorary Doctorates of Humane Letters from the Kansas City University of Medicine and Biosciences and Alma College and the Leonard Tow Humanitarianism in Medicine award from the Arnold P Goldman MD Foundation. He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles. |
17:26 | 2 |
| Close |
Professor Leonard Calabrese
Director & Professor of Medicine, Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute. He is a graduate of the Kansas City University of Medicine and Biosciences. Completed his internal medicine training at the Cleveland Clinic Foundation in Ohio, followed by a fellowship in rheumatic and immunologic disease. Professor Calabrese has received numerous awards, including honorary Doctorates of Humane Letters from the Kansas City University of Medicine and Biosciences and Alma College and the Leonard Tow Humanitarianism in Medicine award from the Arnold P Goldman MD Foundation. He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles. |
01:08 | |
| Evaluation | 17 |
Date of preparation: 3 December 2019